caa a22 4500 465738303 CHVBK 20180323111801.0 cr unu---uuuuu 170327e19900801xx s 000 0 eng 10.1007/BF02244235 doi (NATIONALLICENCE)springer-10.1007/BF02244235 Chronic morphine administration augments benzodiazepine binding and GABAA receptor function [Elektronische Daten] [Fred Lopez, Lawrence Miller, Michael Thompson, Andrew Schatzki, Shelley Chesley, David Greenblatt, Richard Shader] Behavioral and neurochemical evidence indicates links between the opioid and GABA neurotransmitter systems. To assess effects of chronic opiates on the major site of postsynaptic GABAergic activity, the GABAA receptor, we administered chronic morphine and naltrexone to mice and evaluated binding at the benzodiazepine andt-butylbicyclophosphorothionate (TBPS) sites and GABA-dependent chloride uptake. After morphine (3 days), benzodiazepine receptor binding in vivo but not in vitro was increased in cortex compared to placebo-treated mice. TBPS binding was unchanged in cortex, but muscimol-stimulated chloride uptake was increased at low doses of muscimol. Benzodiazepine and TBPS binding and muscimol-stimulated chloride uptake were unchanged in naltrexone-(8 days) compared to placebo-treated mice. When naltrexone was administered previously to block opiate sites, the increases in benzodiazepine binding and chloride uptake observed with chronic morphine were reversed. These results indicate that chronic morphine but not naltrexone enhances benzodiazepine binding and GABAA receptor function, perhaps by an action at opioid receptors. Springer-Verlag, 1990 Morphine nationallicence Naltrexone nationallicence GABA nationallicence Benzodiazepine nationallicence Chloride nationallicence Lopez Fred Division of Clinical Pharmacology, Department of Psychiatry and Pharmacology, Tufts University School of Medicine and New England Medical Center, Boston, MA, USA aut Miller Lawrence Division of Clinical Pharmacology, Department of Psychiatry and Pharmacology, Tufts University School of Medicine and New England Medical Center, Boston, MA, USA aut Thompson Michael Division of Clinical Pharmacology, Department of Psychiatry and Pharmacology, Tufts University School of Medicine and New England Medical Center, Boston, MA, USA aut Schatzki Andrew Division of Clinical Pharmacology, Department of Psychiatry and Pharmacology, Tufts University School of Medicine and New England Medical Center, Boston, MA, USA aut Chesley Shelley Division of Clinical Pharmacology, Department of Psychiatry and Pharmacology, Tufts University School of Medicine and New England Medical Center, Boston, MA, USA aut Greenblatt David Division of Clinical Pharmacology, Department of Psychiatry and Pharmacology, Tufts University School of Medicine and New England Medical Center, Boston, MA, USA aut Shader Richard Division of Clinical Pharmacology, Department of Psychiatry and Pharmacology, Tufts University School of Medicine and New England Medical Center, Boston, MA, USA aut Psychopharmacology Springer-Verlag 101/4(1990-08-01), 545-549 0033-3158 101:4<545 1990 101 213 https://doi.org/10.1007/BF02244235 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02244235 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lopez Fred Division of Clinical Pharmacology, Department of Psychiatry and Pharmacology, Tufts University School of Medicine and New England Medical Center, Boston, MA, USA aut NATIONALLICENCE 700 1- Miller Lawrence Division of Clinical Pharmacology, Department of Psychiatry and Pharmacology, Tufts University School of Medicine and New England Medical Center, Boston, MA, USA aut NATIONALLICENCE 700 1- Thompson Michael Division of Clinical Pharmacology, Department of Psychiatry and Pharmacology, Tufts University School of Medicine and New England Medical Center, Boston, MA, USA aut NATIONALLICENCE 700 1- Schatzki Andrew Division of Clinical Pharmacology, Department of Psychiatry and Pharmacology, Tufts University School of Medicine and New England Medical Center, Boston, MA, USA aut NATIONALLICENCE 700 1- Chesley Shelley Division of Clinical Pharmacology, Department of Psychiatry and Pharmacology, Tufts University School of Medicine and New England Medical Center, Boston, MA, USA aut NATIONALLICENCE 700 1- Greenblatt David Division of Clinical Pharmacology, Department of Psychiatry and Pharmacology, Tufts University School of Medicine and New England Medical Center, Boston, MA, USA aut NATIONALLICENCE 700 1- Shader Richard Division of Clinical Pharmacology, Department of Psychiatry and Pharmacology, Tufts University School of Medicine and New England Medical Center, Boston, MA, USA aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 101/4(1990-08-01), 545-549 0033-3158 101:4<545 1990 101 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer